ATE511396T1 - Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko - Google Patents

Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko

Info

Publication number
ATE511396T1
ATE511396T1 AT08709563T AT08709563T ATE511396T1 AT E511396 T1 ATE511396 T1 AT E511396T1 AT 08709563 T AT08709563 T AT 08709563T AT 08709563 T AT08709563 T AT 08709563T AT E511396 T1 ATE511396 T1 AT E511396T1
Authority
AT
Austria
Prior art keywords
thrombosis
bleeding
risk
thromboserine
prophylaxis
Prior art date
Application number
AT08709563T
Other languages
English (en)
Inventor
Mark Noble
Original Assignee
Thromboserin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thromboserin Ltd filed Critical Thromboserin Ltd
Application granted granted Critical
Publication of ATE511396T1 publication Critical patent/ATE511396T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08709563T 2007-02-28 2008-02-28 Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko ATE511396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89197107P 2007-02-28 2007-02-28
PCT/GB2008/000689 WO2008104789A1 (en) 2007-02-28 2008-02-28 Therapeutic compositions

Publications (1)

Publication Number Publication Date
ATE511396T1 true ATE511396T1 (de) 2011-06-15

Family

ID=39272002

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08709563T ATE511396T1 (de) 2007-02-28 2008-02-28 Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko

Country Status (4)

Country Link
US (1) US9198903B2 (de)
EP (1) EP2129378B1 (de)
AT (1) ATE511396T1 (de)
WO (1) WO2008104789A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129378B1 (de) 2007-02-28 2011-06-01 Thromboserin Limited Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN158970B (de) * 1981-06-09 1987-02-28 Ici Plc
US7091181B2 (en) * 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
IL151164A0 (en) 2000-03-06 2003-04-10 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
EP2129378B1 (de) 2007-02-28 2011-06-01 Thromboserin Limited Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko

Also Published As

Publication number Publication date
WO2008104789A1 (en) 2008-09-04
US9198903B2 (en) 2015-12-01
EP2129378A1 (de) 2009-12-09
US20100093791A1 (en) 2010-04-15
EP2129378B1 (de) 2011-06-01

Similar Documents

Publication Publication Date Title
PH12018500768A1 (en) Purin derivatives for use in the treatment of fab-related diseases
HK1123484A1 (en) Method of using oxidative reductive potential water solution in dental applications
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE602005026724D1 (de) Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden
WO2004014844A3 (en) Aryl and heteroaryl compounds and methods to modulate coagulation
PH12013501790A1 (en) Uses of dpp~iv inhibitors
MX2009012197A (es) Metodos para tratamiento de ulceras en la piel.
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
MX2022000845A (es) Compuestos inhibidores.
ATE414522T1 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
CY1118486T1 (el) Λαπατινιμπη για τη θεραπεια του καρκινου
ATE553760T1 (de) Verwendung von alverin zur behandlung von hauterkrankungen
ATE511396T1 (de) Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
BR112013025197A2 (pt) métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
ATE257384T1 (de) Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
ATE454153T1 (de) 5-ht4 antagonisten zur behandlung von herzversagen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties